Raises Annual
Guidance Record Revenues of $71.7 million, up
16.0% YOYRecord Policies in Force totaled
approximately 389,600, up 8.4% YOY GAAP
Diluted Earnings per Share of $0.22, down 37.1%
YOY Record Adjusted Earnings per Share of
$0.61, up 32.6% YOY
Health Insurance Innovations, Inc. (NASDAQ:HIIQ), a leading
cloud-based technology platform and distributor of affordable
individual and family health insurance and supplemental plans,
today announced financial results for the second quarter ended
June 30, 2018. The Company will host a live conference call on
Thursday, August 2, 2018, at 8:30 A.M. EST.
Second quarter 2018 Financial
Highlights
- Record revenue was $71.7 million, compared to $61.8 million in
the second quarter of 2017, an increase of 16.0%.
- Record total collections from members (premium equivalents) of
$111.2 million compared to $98.9 million in the second quarter of
2017, an increase of 12.4%.
- Net income was $4.0 million, compared to $7.0 million in the
second quarter of 2017, a decrease of 42.9%. Drivers include
severance expense payable to the founder and several other
employees and higher stock-based compensation in the second quarter
of 2018.
- Record adjusted EBITDA (earnings before interest, taxes,
depreciation and amortization) was $14.2 million, compared to $12.6
million in the second quarter of 2017, an increase of 12.7%.
- GAAP diluted earnings per share was $0.22, compared to $0.35 in
the second quarter of 2017, down 37.1% YOY. Drivers include
severance expense payable to the founder and several other
employees and higher stock-based compensation in the second quarter
of 2018.
- Record adjusted earnings per share, also referred to as
adjusted net income per share, or adjusted EPS, was $0.61 compared
to $0.46 in the second quarter of 2017, an increase of 32.6%.
- Record policies in force as of June 30, 2018, totaled
approximately 389,600, compared to 359,500 in the second quarter of
2017, an increase of 8.4%.
Premium equivalents, adjusted EBITDA, and
adjusted EPS are non-GAAP financial measures. See the
reconciliations of these measures to their respective most directly
comparable GAAP measure included within this press release.
2018 Full Year Guidance
The Company raises its annual guidance of
revenue for 2018 to be between $293 million and $303 million or
grow approximately 17% to 21% year-over-year, adjusted EBITDA to be
between $55 million and $58 million or grow approximately 21% to
27% year-over-year, and adjusted EPS to be between $2.47 and $2.57
or grow approximately 50% to 56% year-over-year. These
guidance numbers are based on the Company’s current method of
accounting for revenue. As an emerging growth company, it
will be adopting the revised revenue recognition standard, known as
ASC 606, in the fourth quarter of 2018 for the full year ended
December 31, 2018.
"Q2 was a strong quarter with record revenue, record earnings
and record policies in force. We are pleased to have beaten market
expectations and following a strong first half of the year, to be
able to raise guidance for the rest of 2018. We look forward to
launching the next generation of our technology platform later in
the year and we are prepared for the expanding opportunities in our
market." said Gavin Southwell, HIIQ's Chief Executive Officer and
President.
Second quarter 2018 Financial Discussion
Second quarter revenues of $71.7 million
increased 16.0%, compared to the second quarter in 2017, driven by
an increase in policies in force, favorable commission margins, and
improved discount benefit plan offerings.
Total selling, general & administrative
expense ("SG&A") was $19.7 million (27.5% of revenues) in the
second quarter of 2018, compared to $14.7 million (23.8% of
revenues) in the same period in 2017. Q2 SG&A included cash
based severance expense of $3.0 million and $0.8 million of
non-cash based severance expense primarily related to the
termination of the Company’s founder and several other employees.
Core SG&A, defined as total SG&A adjusted for stock-based
compensation, transaction costs, indemnity and other related legal
costs, severance, restructuring and other costs, and marketing
leads and advertising expense, was $10.2 million (14.2% of
revenues) in the second quarter of 2018, compared to $11.1 million
(18.0% of revenues) in the same period in 2017. A reconciliation of
Core SG&A to SG&A is included within this press
release.
Net income was $4.0 million in the second
quarter of 2018, compared to $7.0 million in the same period in
2017, a decrease of 42.9%. Second quarter 2018 included a cash
based severance expense of $3.0 million. Additionally, stock-based
compensation was $2.6 million higher in the second quarter of 2018
as compared to the prior year period. EBITDA was $6.7 million in
the second quarter of 2018, compared to $10.7 million in the same
period in 2017, a decrease of 37.4%.
Adjusted EBITDA was $14.2 million in the second
quarter of 2018, an increase of 12.7% compared to $12.6 million in
the same period in 2017. Adjusted EBITDA as a percentage of revenue
was 19.8% in the second quarter of 2018, compared to 20.3% in the
same period in 2017. Adjusted EBITDA is calculated by taking EBITDA
and adjusting for items such as stock-based compensation and
related costs and items that are not part of regular operating
activities, including indemnity and other related legal costs,
severance, restructuring, and acquisition costs. A reconciliation
of net income to EBITDA and adjusted EBITDA for the three and six
months ended June 30, 2018 and 2017 is included within this press
release.
GAAP diluted EPS for the second quarter of 2018
was $0.22, compared to $0.35 in the same period in 2017. Second
quarter 2018 GAAP diluted EPS was unfavorably impacted by the
previously described severance expense. Additionally, the higher
stock-based compensation in the second quarter of 2018 had an
unfavorable impact on GAAP diluted EPS.
Adjusted EPS for the second quarter of 2018 was
$0.61, compared to $0.46 in 2017. The increase in Adjusted EPS was
driven by higher revenue from greater policies in force, continued
scalability as well as a lower pro-forma statutory tax rate of 24%,
compared to 38% used in the prior period. A reconciliation of net
income to adjusted net income per share is included within this
press release.
The Company makes advances to distributors based
on actual sales. These advanced commissions assist distributors
with working capital. The Company recovers advances on an ongoing
basis from future commissions on premiums, which are collected over
the period in which policies renew. At June 30, 2018, the short-
and long-term advanced commission balance was $37.6 million, a $1.9
million decrease from the December 31, 2017 year-end balance
of $39.5 million.
Cash and cash equivalents as of June 30,
2018 totaled $49.2 million, an increase of $8.3 million from the
December 31, 2017 year-end balance. The Company repurchased
115,245 shares of its common stock in the second quarter of 2018
for $3.8 million as part of its previously announced share
repurchase program. The company expects to continue to execute on
its buyback authorization for the remainder of 2018 and beyond.
On June 7, 2018, the Company terminated without cause Michael
Kosloske, founder and Chief of Product Innovation. Mr. Kosloske
will continue to serve as a director of the Company. Additionally,
on June 7, 2018 the Company was informed by Mr. Kosloske that
entities controlled by Mr. Kosloske sold an aggregate of 1,300,000
shares of the Company’s Class A common stock.
Regulatory Update
Today the departments of Health and Human
Services, Labor and the Treasury issued a final rule to help
Americans struggling to afford health coverage find new and more
affordable options. The rule allows, starting October 1st, 2018,
for the sale and renewal of short-term, limited duration plans to
cover an initial period of less than 12 months. Additionally,
carriers will be able to make these plans renewable for up to 36
months. Previously, the rule limited duration to less than three
months. “HIIQ shares the Departments’ concern with respect to the
rising cost of health insurance in the individual market and
welcomes any measures taken to improve the availability of
insurance products that meet consumer demands and needs,” Mr. Gavin
Southwell said. “We also believe that this rule change will improve
consumer choice and increase competition and affordability in the
individual health insurance market.”
As previously disclosed, the Company is the
subject of a multistate market conduct examination. The Company has
been cooperating with all regulatory inquiries and is engaged in
ongoing discussions towards resolution.
Conference Call and Webcast
The Company will host an earnings conference
call on August 2, 2018 at 8:30 A.M. Eastern time. All
interested parties can join the call by dialing (877)
407-9039 or (201) 689-8470; the conference ID is 13681866.
A webcast of the call may be accessed in the Investor Relations
section of Health Insurance Innovations’ website at
http://investor.hiiquote.com/events-and-presentations. An archive
of the call will be available for 30 days through the same
website.
About Health Insurance Innovations, Inc.
(HIIQ)
HIIQ is a market leading cloud-based technology
platform and distributor of innovative health insurance products
that are affordable and meet the consumer's needs. HIIQ helps
develop insurance products through our relationships with
best-in-class insurance companies and markets them via its broad
distribution network of third party licensed insurance agents
across the nation, its call center network and its unique online
capability. Additional information about HIIQ can be found at
HiiQuote.com. HIIQ’s Consumer Division includes
AgileHealthInsurance.com, a website for researching, comparing and
purchasing short-term health insurance products online and
HealthPocket.com, a free website that compares and ranks all health
insurance plans, and uses objective data to publish unbiased health
insurance market analyses and other consumer advocacy research.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
statements other than historical fact, and may include statements
relating to goals, plans and projections regarding new markets,
products, services, growth strategies, anticipated trends in our
business and anticipated changes and developments in the United
States health insurance system and laws. Forward-looking statements
are based on HIIQ’s current assumptions, expectations and beliefs
are generally identifiable by use of words “may,” “might,” “will,”
“should,” “expects,” “plans,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential” or “continue,” or similar
expressions and involve significant risks and uncertainties that
could cause actual results, developments and business decisions to
differ materially from those contemplated by these statements.
These risks and uncertainties include, among other things, our
ability to maintain relationships and develop new relationships
with health insurance carriers and distributors, our ability to
retain our members, the demand for products offered through our
platform, state regulatory oversight and examinations of us and our
carriers and distributors, legal and regulatory compliance by our
carriers and distributors, the amount of commissions paid to us or
changes in health insurance plan pricing practices, competition,
changes and developments in the United States health insurance
system and laws, and HIIQ’s ability to adapt to them, the ability
to maintain and enhance our name recognition, difficulties arising
from acquisitions or other strategic transactions, and our ability
to build the necessary infrastructure and processes to maintain
effective controls over financial reporting. These and other risk
factors that could cause actual results to differ materially from
those expressed or implied in our forward-looking statements will
be discussed in HIIQ's Annual Report on Form 10-K filed with the
Securities and Exchange Commission (SEC) as well as other documents
that may be filed by HIIQ from time to time with the Securities and
Exchange Commission, which are available at www.sec.gov. Any
forward-looking statement made by us in this press release is based
only on information currently available to us and speaks only as of
the date on which it is made. You should not rely on any
forward-looking statement as representing our views in the future.
We undertake no obligation to publicly update any forward-looking
statement, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Non-GAAP Financial
Information
To supplement HIIQ’s financial information
presented in accordance with generally accepted accounting
principles in the United States of America, or GAAP, HIIQ presents
certain financial measures that are not prepared in accordance with
GAAP, including premium equivalents, adjusted EBITDA, adjusted EPS,
and Core SG&A. These non-GAAP financial measures, which are
defined below, should not be considered in isolation from, or as a
substitute for, financial information prepared in accordance with
GAAP. These non-GAAP financial measures are not based on any
standardized methodology prescribed by GAAP and are not necessarily
comparable to similarly-titled measures presented by other
companies.
HIIQ is presenting these non-GAAP financial
measures to assist investors in seeing HIIQ’s operating results
through the eyes of management and because HIIQ believes that these
measures provide a useful tool for investors to use in assessing
HIIQ’s operating performance against prior period operating results
and against business objectives. HIIQ uses the non-GAAP financial
measures in evaluating its operating results and for financial and
operational decision-making purposes.
The accompanying tables provide more detail on
the GAAP financial measures that are most directly comparable to
the non-GAAP financial measures described above and the related
reconciliations between these financial measures.
HEALTH INSURANCE INNOVATIONS,
INC. |
Condensed Consolidated Balance
Sheets |
($ in thousands, except share and per share
data) |
|
|
|
|
|
June 30, 2018 |
|
December 31, 2017 |
|
(unaudited) |
|
|
Assets |
|
|
|
Current
assets: |
|
|
|
Cash and cash equivalents |
$ |
49,220 |
|
|
$ |
40,907 |
|
Restricted cash |
15,554 |
|
|
14,920 |
|
Accounts receivable, net, prepaid expenses and other current
assets |
1,692 |
|
|
2,227 |
|
Advanced commissions, net |
34,844 |
|
|
39,549 |
|
Income taxes receivable |
1,766 |
|
|
— |
|
Total
current assets |
103,076 |
|
|
97,603 |
|
Long-term
advanced commissions |
2,773 |
|
|
— |
|
Property
and equipment, net |
5,396 |
|
|
5,408 |
|
Goodwill |
41,076 |
|
|
41,076 |
|
Intangible
assets, net |
5,015 |
|
|
5,942 |
|
Deferred
tax assets |
25,445 |
|
|
14,960 |
|
Other
assets |
92 |
|
|
96 |
|
Total assets |
$ |
182,873 |
|
|
$ |
165,085 |
|
|
|
|
|
Liabilities and stockholders’ equity |
|
|
|
Current
liabilities: |
|
|
|
Accounts payable and accrued expenses |
$ |
37,173 |
|
|
$ |
39,725 |
|
Deferred revenue |
239 |
|
|
662 |
|
Income taxes payable |
— |
|
|
787 |
|
Due to member |
2,337 |
|
|
1,775 |
|
Other current liabilities |
8 |
|
|
5 |
|
Total current liabilities |
39,757 |
|
|
42,954 |
|
Due to
member |
25,085 |
|
|
15,096 |
|
Other
liabilities |
23 |
|
|
34 |
|
Total liabilities |
64,865 |
|
|
58,084 |
|
Commitments
and contingencies |
|
|
|
Stockholders’ equity: |
|
|
|
Class A common stock (par value $0.001 per share, 100,000,000
shares authorized; 14,242,049 and 12,731,758 shares issued as of
June 30, 2018 and December 31, 2017, respectively; 13,707,715 and
12,350,981 shares outstanding as of June 30, 2018 and December 31,
2017, respectively) |
14 |
|
|
13 |
|
Class B
common stock (par value $0.001 per share, 20,000,000 shares
authorized; 2,541,667 and 3,841,667 shares issued and outstanding
as of June 30, 2018 and December 31, 2017, respectively) |
3 |
|
|
4 |
|
Preferred
stock (par value $0.001 per share, 5,000,000 shares authorized; no
shares issued and outstanding as of June 30, 2018 and December 31,
2017) |
— |
|
|
— |
|
Additional
paid-in capital |
87,469 |
|
|
71,770 |
|
Treasury
stock, at cost (534,334 and 380,777 shares as of June 30, 2018 and
December 31, 2017, respectively) |
(11,998 |
) |
|
(6,887 |
) |
Retained earnings |
26,317 |
|
|
19,305 |
|
Total Health Insurance Innovations, Inc. stockholders’
equity |
101,805 |
|
|
84,205 |
|
Noncontrolling interests |
16,203 |
|
|
22,796 |
|
Total stockholders’ equity |
118,008 |
|
|
107,001 |
|
Total liabilities and stockholders' equity |
$ |
182,873 |
|
|
$ |
165,085 |
|
|
|
|
|
|
|
|
|
|
HEALTH INSURANCE INNOVATIONS,
INC. |
|
Condensed Consolidated Statements of
Income (unaudited) |
($ in thousands, except share and per
share data) |
|
|
|
|
|
Three Months Ended June
30, |
|
Six Months Ended June
30, |
|
2018 |
|
2017 |
|
2018 |
|
2017 |
Revenues
(premium equivalents of $111,159 and $98,896 for the three months
ended June 30, 2018 and 2017, respectively and $216,135 and
$189,836 for the six months ended June 30, 2018 and 2017,
respectively) |
$ |
71,724 |
|
|
$ |
61,783 |
|
|
$ |
139,474 |
|
|
$ |
117,651 |
|
Operating
expenses: |
|
|
|
|
|
|
|
Third-party commissions |
43,885 |
|
|
35,108 |
|
|
85,097 |
|
|
66,543 |
|
Credit card and ACH fees |
1,371 |
|
|
1,232 |
|
|
2,748 |
|
|
2,415 |
|
Selling, general and administrative |
19,724 |
|
|
14,697 |
|
|
35,937 |
|
|
29,954 |
|
Depreciation and amortization |
1,220 |
|
|
992 |
|
|
2,385 |
|
|
1,930 |
|
Total operating expenses |
66,200 |
|
|
52,029 |
|
|
126,167 |
|
|
100,842 |
|
Income from operations |
5,524 |
|
|
9,754 |
|
|
13,307 |
|
|
16,809 |
|
|
|
|
|
|
|
|
|
Other
(income) expense: |
|
|
|
|
|
|
|
Interest (income) expense |
(28 |
) |
|
1 |
|
|
(54 |
) |
|
— |
|
Other expense |
31 |
|
|
1 |
|
|
59 |
|
|
4 |
|
Net income before income taxes |
5,521 |
|
|
9,752 |
|
|
13,302 |
|
|
16,805 |
|
Provision for income taxes |
1,495 |
|
|
2,800 |
|
|
3,291 |
|
|
1,331 |
|
Net
income |
4,026 |
|
|
6,952 |
|
|
10,011 |
|
|
15,474 |
|
Net income attributable to noncontrolling interests |
1,160 |
|
|
2,569 |
|
|
2,999 |
|
|
5,257 |
|
Net income
attributable to Health Insurance Innovations, Inc. |
$ |
2,866 |
|
|
$ |
4,383 |
|
|
$ |
7,012 |
|
|
$ |
10,217 |
|
|
|
|
|
|
|
|
|
Per
share data: |
|
|
|
|
|
|
|
Net
income per share attributable to Health Insurance Innovations,
Inc. |
|
|
|
|
|
|
|
Basic |
$ |
0.24 |
|
|
$ |
0.38 |
|
|
$ |
0.60 |
|
|
$ |
1.00 |
|
Diluted |
$ |
0.22 |
|
|
$ |
0.35 |
|
|
$ |
0.54 |
|
|
$ |
0.91 |
|
Weighted average Class A common shares
outstanding |
|
|
|
|
|
|
|
Basic |
11,934,760 |
|
|
11,550,204 |
|
|
11,763,221 |
|
|
10,228,564 |
|
Diluted |
13,175,814 |
|
|
12,365,914 |
|
|
12,917,999 |
|
|
11,220,687 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HEALTH INSURANCE INNOVATIONS,
INC. |
|
|
Condensed Consolidated Statements of Cash Flows
(unaudited) |
($ in thousands, except share and per share
data) |
|
|
|
Six Months Ended June
30, |
|
2018 |
|
2017 |
Operating activities: |
|
|
|
Net
income |
$ |
10,011 |
|
|
$ |
15,474 |
|
Adjustments
to reconcile net income to net cash provided by operating
activities: |
|
|
|
Stock-based compensation |
6,160 |
|
|
1,755 |
|
Depreciation and amortization |
2,385 |
|
|
1,930 |
|
Deferred income taxes |
632 |
|
|
762 |
|
Changes in
operating assets and liabilities: |
|
|
|
Decrease in accounts receivable, prepaid expenses and other
assets |
556 |
|
|
218 |
|
Decrease in advanced commissions |
1,932 |
|
|
6,295 |
|
Increase in income taxes receivable |
(1,766 |
) |
|
(1,282 |
) |
Decrease in income taxes payable |
(787 |
) |
|
(2,121 |
) |
(Decrease) increase in accounts payable, accrued expenses and
other liabilities |
(2,560 |
) |
|
297 |
|
Decrease in deferred revenue |
(423 |
) |
|
(132 |
) |
Net cash
provided by operating activities |
16,140 |
|
|
23,196 |
|
Investing activities: |
|
|
|
Capitalized internal-use software |
(880 |
) |
|
(1,410 |
) |
Purchases of property and equipment |
(223 |
) |
|
(47 |
) |
Net cash
used in investing activities |
(1,103 |
) |
|
(1,457 |
) |
Financing activities: |
|
|
|
Payments for noncompete obligation |
— |
|
|
(96 |
) |
Payments related to tax withholding for share-based
compensation |
(1,310 |
) |
|
(185 |
) |
Issuances of Class A common stock under equity compensation
plans |
4 |
|
|
20 |
|
Purchases of Class A common stock pursuant to share
repurchase plan |
(3,801 |
) |
|
— |
|
Distributions to member |
(983 |
) |
|
(4,494 |
) |
Net cash
used in financing activities |
(6,090 |
) |
|
(4,755 |
) |
Net
increase in cash and cash equivalents, and restricted cash |
8,947 |
|
|
16,984 |
|
Cash and
cash equivalents, and restricted cash at beginning of period |
55,827 |
|
|
25,370 |
|
Cash and
cash equivalents, and restricted cash at end of period |
$ |
64,774 |
|
|
$ |
42,354 |
|
|
|
|
|
Supplemental cash flow information: |
|
|
|
Cash paid during the period for: |
|
|
|
Income taxes, net |
$ |
5,321 |
|
|
$ |
3,988 |
|
Interest |
6 |
|
|
10 |
|
Non-cash investing activities: |
|
|
|
Capitalized stock-based compensation |
$ |
343 |
|
|
$ |
— |
|
Non-cash financing activities: |
|
|
|
Change in due to member related to Exchange Agreement |
$ |
9,989 |
|
|
$ |
18,619 |
|
Change in deferred tax asset related to Exchange
Agreement |
(11,118 |
) |
|
(20,732 |
) |
Issuance of Class A common stock in a private offering
related to Exchange Agreement |
9,175 |
|
|
16,487 |
|
Exchange of Class B membership interests related to Exchange
Agreement |
(8,047 |
) |
|
(14,374 |
) |
Declared but unpaid distribution to member of Health Plan
Intermediaries, LLC |
1,200 |
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Net Income to EBITDA and
Adjusted EBITDA |
(unaudited) |
($ in thousands) |
|
|
|
|
|
Three Months Ended June
30, |
|
Six Months Ended June
30, |
|
2018 |
|
2017 |
|
2018 |
|
2017 |
Net
income |
$ |
4,026 |
|
|
$ |
6,952 |
|
|
$ |
10,011 |
|
|
$ |
15,474 |
|
Interest
(income) expense |
(28 |
) |
|
1 |
|
|
(54 |
) |
|
— |
|
Depreciation and amortization |
1,220 |
|
|
992 |
|
|
2,385 |
|
|
1,930 |
|
Provision
for income taxes |
1,495 |
|
|
2,800 |
|
|
3,291 |
|
|
1,331 |
|
EBITDA (1) |
6,713 |
|
|
10,745 |
|
|
15,633 |
|
|
18,735 |
|
Stock-based
compensation and related costs (2) |
3,601 |
|
|
1,031 |
|
|
6,265 |
|
|
2,143 |
|
Transaction
costs |
163 |
|
|
450 |
|
|
219 |
|
|
756 |
|
Indemnity
and other related legal costs |
745 |
|
|
360 |
|
|
1,033 |
|
|
648 |
|
Severance,
restructuring and other charges |
2,952 |
|
|
3 |
|
|
2,952 |
|
|
248 |
|
Adjusted EBITDA (3) |
$ |
14,174 |
|
|
$ |
12,589 |
|
|
$ |
26,102 |
|
|
$ |
22,530 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Net Income to Adjusted
Net Income per Share |
(unaudited) |
($ in thousands except per share
data) |
|
|
|
|
|
Three Months Ended |
|
Six Months Ended |
|
June 30, |
|
June 30, |
|
2018 |
|
2017 |
|
2018 |
|
2017 |
Net
income |
$ |
4,026 |
|
|
$ |
6,952 |
|
|
$ |
10,011 |
|
|
$ |
15,474 |
|
Interest
(income) expense |
(28 |
) |
|
1 |
|
|
(54 |
) |
|
— |
|
Amortization |
464 |
|
|
512 |
|
|
927 |
|
|
1,023 |
|
Provision
for income taxes |
1,495 |
|
|
2,800 |
|
|
3,291 |
|
|
1,331 |
|
Stock-based
compensation and related costs |
3,601 |
|
|
1,031 |
|
|
6,265 |
|
|
2,143 |
|
Transaction
costs |
163 |
|
|
450 |
|
|
219 |
|
|
756 |
|
Indemnity
and other related legal costs |
745 |
|
|
360 |
|
|
1,033 |
|
|
648 |
|
Severance,
restructuring and other charges |
2,952 |
|
|
3 |
|
|
2,952 |
|
|
248 |
|
Adjusted pre-tax income |
13,418 |
|
|
12,109 |
|
|
24,644 |
|
|
21,623 |
|
Pro forma
income taxes |
(3,220 |
) |
|
(4,601 |
) |
|
(5,915 |
) |
|
(8,217 |
) |
Adjusted net income (4) |
$ |
10,198 |
|
|
$ |
7,508 |
|
|
$ |
18,729 |
|
|
$ |
13,406 |
|
Total
weighted average diluted share count |
16,675 |
|
|
16,208 |
|
|
16,587 |
|
|
16,156 |
|
Adjusted
net income per share (5) |
$ |
0.61 |
|
|
$ |
0.46 |
|
|
$ |
1.13 |
|
|
$ |
0.83 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) EBITDA is defined as net income before interest expense,
income taxes and depreciation and amortization. We have included
EBITDA in this report because it is key measure used by our
management and Board of Directors to understand and evaluate our
core operating performance and trends, to prepare and approve our
annual budget and to develop short- and long-term operational
plans. In particular, the exclusion of certain expenses in
calculating EBITDA can provide a useful measure for
period-to-period comparisons of our business. However, EBITDA does
not represent, and should not be considered as, an alternative to
net income or cash flows from operations, each as determined in
accordance with generally accepted accounting principles in the
United States of America (“GAAP”). Other companies may calculate
EBITDA differently than we do. EBITDA has limitations as an
analytical tool, and you should not consider it in isolation or as
a substitute for analysis of our results as reported under
GAAP.
(2) During the 3 months ended June 30, 2018, the Company began
including in adjusted EBITDA, the payments related to employer
taxes for vesting and exercises of stock-based compensation. For
period-over-period comparability, the Company has included these
amounts in 2017 previously reported numbers. For the three and six
months ended June 30, 2017, the impact on adjusted EBITDA was an
approximate increase of $66,700 and $359,600, respectively.
This resulted in no change to adjusted net income per share for the
three months ended June 30, 2017 and a $0.01 increase in adjusted
net income per share for the six months ended June 30, 2017.
(3) To calculate adjusted EBITDA, we calculate EBITDA, which is
then further adjusted for items such as stock-based compensation
and related costs and items that are not part of regular operating
activities, including tax receivable adjustments, severance,
restructuring, indemnity and other related legal costs, and
acquisition costs. Adjusted EBITDA does not represent, and should
not be considered as, an alternative to net income or cash flows
from operations, each as determined in accordance with GAAP. We
have presented adjusted EBITDA because we consider it an important
supplemental measure of our performance and believe that it is
frequently used by analysts, investors and other interested parties
in the evaluation of companies. Other companies may calculate
adjusted EBITDA differently than we do. Adjusted EBITDA has
limitations as an analytical tool, and you should not consider it
in isolation or as a substitute for analysis of our results as
reported under GAAP.
(4) To calculate adjusted net income, we calculate net income
then add back amortization (but not depreciation), interest, tax
expense, stock-based compensation and related costs, and other
items that are not part of regular operating activities, including,
tax receivable adjustments, severance, restructuring, indemnity and
other related legal costs, and acquisition costs. From adjusted
pre-tax net income we apply a pro-forma tax expense calculated at
an assumed rate of 24% for the three and six months ended June 30,
2018 and 38% for the three and six months ended June 30, 2017. We
believe that when measuring Company and executive performance
against the adjusted net income measure, applying a pro forma tax
rate better reflects the performance of the Company without regard
to the Company’s organizational tax structure. We have included
adjusted net income in this report because it is a key performance
measure used by our management to understand and evaluate our core
operating performance and trends and because we believe it is
frequently used by analysts, investors and other interested parties
in their evaluation of our company. Other companies may calculate
this measure differently than we do. Adjusted net income has
limitations as an analytical tool, and you should not consider it
in isolation or substitution for earnings per share as reported
under GAAP.
(5) Adjusted net income per share is computed by dividing
adjusted net income by the total number of diluted Class A and
Class B shares of our common stock for each period. We have
included adjusted net income per share in this report because it is
a key measure used by our management to understand and evaluate our
core operating performance and trends and because we believe it is
frequently used by analysts, investors and other interested parties
in the evaluation of companies. Other companies may calculate this
measure differently than we do. Adjusted net income per share has
limitations as an analytical tool, and you should not consider it
in isolation or as a substitute for earnings per share as reported
under GAAP.
|
|
|
|
Reconciliation of Premium Equivalents to
Revenues |
(unaudited) |
($ in thousands) |
|
|
|
|
|
Three Months Ended June
30, |
|
Six Months Ended June
30, |
|
2018 |
|
2017 |
|
2018 |
|
2017 |
Premium
equivalents (1) |
$ |
111,159 |
|
|
$ |
98,896 |
|
|
$ |
216,135 |
|
|
$ |
189,836 |
|
Less risk
premium |
37,570 |
|
|
35,502 |
|
|
73,116 |
|
|
69,043 |
|
Less
amounts earned by third party obligors |
1,865 |
|
|
1,611 |
|
|
3,545 |
|
|
3,142 |
|
Revenues |
$ |
71,724 |
|
|
$ |
61,783 |
|
|
$ |
139,474 |
|
|
$ |
117,651 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Premium equivalents is defined as our total collections,
including the combination of premiums, fees for discount benefit
plans, third-party commissions and referral fees. All amounts
not paid out as risk premium to carriers or paid out to other
third-party obligors are considered to be revenues for financial
reporting purposes. We have included premium equivalents in this
report because it is a key measure used by our management to
understand and evaluate our core operating performance and trends,
to prepare and approve our annual budget, and to develop short- and
long-term operational plans. In particular, the inclusion of
premium equivalents can provide a useful measure for
period-to-period comparisons of our business. This financial
measurement is considered a non-GAAP financial measure and is not
recognized under generally accepted accounting principles in the
United States of America (“GAAP”) and should not be used as, and is
not an alternative to, revenues as a measure of our operating
performance.
Summary of Selected
Metrics(unaudited)($ in
thousands)
|
Submitted Applications
during the Three Months Ended June 30, |
|
|
|
|
|
|
2018 |
|
2017 |
|
Change |
IFP |
92,100 |
|
95,900 |
|
(4.0 |
)% |
Supplemental products |
64,600 |
|
66,900 |
|
(3.4 |
)% |
Total
(1) |
156,700 |
|
162,800 |
|
(3.7 |
)% |
|
Policies in Force as of June
30, |
|
|
|
2018 |
|
2017 |
|
Change |
IFP |
196,800 |
|
|
185,900 |
|
|
5.9 |
% |
Supplemental products |
192,800 |
|
|
173,600 |
|
|
11.1 |
% |
Total |
389,600 |
|
|
359,500 |
|
|
8.4 |
% |
|
Submitted IFP Applications by
Channel |
|
Q2’17 |
|
Q3’17 |
|
Q4’17 |
|
Q1’18 |
|
Q2’18 |
eCommerce |
13,500 |
|
20,600 |
|
27,200 |
|
18,900 |
|
18,700 |
All Others
(1) |
82,400 |
|
72,500 |
|
98,600 |
|
73,100 |
|
73,400 |
Total |
95,900 |
|
93,100 |
|
125,800 |
|
92,000 |
|
92,100 |
|
Core SG&A as a Percentage of
Revenue |
|
Q2’17 |
|
Q3’17 |
|
Q4’17 |
|
Q1’18 |
|
Q2'18 |
Total
SG&A |
$14,697 |
|
$15,503 |
|
$18,989 |
|
$16,213 |
|
$19,724 |
Less:
Stock-based compensation and related costs |
|
1,031 |
|
|
2,782 |
|
|
2,993 |
|
|
2,633 |
|
|
3,601 |
Less (add):
Transaction costs |
|
450 |
|
|
5 |
|
|
(16) |
|
|
56 |
|
|
163 |
Less:
Indemnity and other related legal costs |
|
360 |
|
|
238 |
|
|
672 |
|
|
287 |
|
|
745 |
Less:
Severance, restructuring and other charges |
|
3 |
|
|
— |
|
|
— |
|
|
— |
|
|
2,952 |
Less:
Marketing and Advertising |
|
1,800 |
|
|
2,249 |
|
|
3,657 |
|
|
2,232 |
|
|
2,071 |
Core
SG&A (1) |
$11,053 |
|
$10,229 |
|
$11,683 |
|
$11,005 |
|
$10,192 |
% of
Revenue |
|
17.9% |
|
|
16.2% |
|
|
16.8% |
|
|
16.2% |
|
|
14.2% |
(1) Core SG&A is defined as total SG&A
adjusted for stock-based compensation and related costs,
transaction costs, severance, indemnity and other related legal
costs, restructuring and other costs, and marketing leads and
advertising expense.
Contacts:
Health Insurance Innovations, Inc.:Michael HershbergerChief
Financial Officer(813) 397-1187mhershberger@hiiquote.com
Investor Contact:John EvansPIR Communications(415)
309-0230IR@hiiquote.com
Health Insurance Innovat... (NASDAQ:HIIQ)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Health Insurance Innovat... (NASDAQ:HIIQ)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024